Top Markets
#1 0G 0G +40.59%
#2 Merlin's Seal BTC Merlin's Seal BTC +37.85%
#3 StonkBroker StonkBroker +33.99%
#4 Useless Coin Useless Coin +33.54%
#5 SAFEcoin SAFEcoin +28.88%
#6 Dogs Dogs +23.94%
#7 rsERG rsERG +22.27%
#8 Pons Pons +22.22%
#9 ICON ICON +22.10%
#10 Zora Zora +21.17%
Coin of the day
0G 0G
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Qyuns Therapeutics Co., Ltd. Qyuns Therapeutics Co., Ltd.

Qyuns Therapeutics Co., Ltd.

2509
Kedudukan dalam Saham #13603
Qyuns Therapeutics Co., Ltd., a biotechnology company established in 2015 and... Qyuns Therapeutics Co., Ltd., a biotechnology company established in 2015 and headquartered in Taizhou, China, is focused on the discovery and clinical advancement of biologic therapies. Its primary mission is to address autoimmune and allergic diseases within the People's Republic of China. The company boasts a robust pipeline of investigational treatments. Its lead candidate, QX002N, an interleukin (IL)-17A inhibitor, is currently undergoing Phase III clinical trials for the management of ankylosing spondylitis and lupus nephritis. Another key asset, QX005N, a monoclonal antibody engineered to block IL-4Ra, has successfully concluded its Phase II clinical development. This compound targets a wide array of conditions, including atopic dermatitis, prurigo nodularis, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria (CSU), asthma, and chronic obstructive pulmonary disease (COPD). Further advanced programs include QX001S, an IL-12/IL-23p40 inhibitor, also in Phase III trials for psoriasis (Ps) and inflammatory bowel diseases such as ulcerative colitis/Crohn's disease (CD). QX004N, an IL-23p19 inhibitor, is progressing through Phase II for Ps and CD. Additionally, early-stage clinical development encompasses QX006N, an IFNAR1-targeting monoclonal antibody in Phase Ib for systemic lupus erythematosus, and QX008N, a humanized IgG1 monoclonal antibody targeting thymic stromal lymphopoietin, also in Phase Ib for moderate-to-severe asthma and COPD. Qyuns is also developing several compounds at an earlier stage, including QX007N, which targets IL-33 for COPD and asthma; QX013N, aimed at c-kit for CSU; and QX010N, an IL-31R inhibitor for pruritus. Beyond its drug development endeavors, the company engages in the research, development, and manufacturing of pharmaceutical products, and provides specialized technical consultation services.
Harga Saham
$2.13
Modal Pasaran
$476.06M
Perubahan (1 hari)
-2.00%
Perubahan (1 tahun)
-30.98%
Negara
CN
Perdagangan Qyuns Therapeutics Co., Ltd. (2509)

Kategori

Healthcare
Sejarah harga saham bagi Qyuns Therapeutics Co., Ltd. (2509)
Harga penutupan tertinggi: $2.21 pada 2026-08-01

Harga penutupan terendah: $2.78 pada 2024-03-01
Sejarah harga saham Qyuns Therapeutics Co., Ltd. dari 2024 hingga 2026
Prestasi harga saham tahunan
Tahun Prestasi
2026 (TTM) 2.82%
2025 115.05%
2024 0.00%
Harga saham bagi syarikat atau pesaing serupa
Syarikat Harga saham Perubahan 1thn% Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $542.32 38.69%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.02K 43.79%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $121.01 -13.08%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $139.87 480.61%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $749.90 5.87%
CH